Sisram Medical Reports Solid Growth in 2025

Core Insights - Sisram Medical reported solid growth in 2025, driven by strong performance in international markets and an accelerating injectables business [1] - The company achieved a revenue of US$365.3 million, marking a 4.7% year-on-year increase, with injectables revenue soaring by 185.6% to US$28.0 million [6] - The company is focusing on building an integrated medical aesthetics ecosystem, enhancing its product offerings and expanding its market presence [8][9] Financial Highlights - Revenue for the year ended December 31, 2025, was US$365.3 million, a 4.7% increase year-on-year [6] - Injectables revenue reached US$28.0 million, reflecting a significant increase of 185.6% year-on-year [6] - Gross profit margin decreased to 58.9% from 62.1% in 2024, while net profit decreased by 13.1% to US$25.0 million [6] Key Achievements - The energy-based device (EBD) portfolio reinforced Sisram's leadership in the global aesthetics market, with Alma Harmony receiving multiple awards [4] - DAXXIFY achieved regulatory approval and initial clinical applications in China, with over 10,000 units shipped [5] - The company launched Universkin by Alma, an AI-powered personalized skincare platform, enhancing its service offerings [7] Market Expansion - International markets (excluding North America) grew by 20.1% year-on-year, with APAC revenue increasing by 26.9% to US$147.4 million [6] - Revenue in Europe and the Middle East and Africa was US$56.4 million and US$36.4 million, representing increases of 11.7% and 5.3% year-on-year, respectively [6] - North America revenue decreased by 19.2% to US$111.0 million [6] Strategic Outlook - Sisram plans to establish a manufacturing facility in China to support regional R&D and production [8] - The company aims to prioritize the commercialization of DAXXIFY in mainland China and advance regulatory approvals for additional injectables [9] - Sisram will explore strategic M&A opportunities to enhance its ecosystem and innovation capabilities [9]